IL2 and acute myeloid leukemia: Additionally, nivolumab, which targets the PD-1/PD-L1 axis to revert inactivation of T cells, was reported not to reduce relapse risk in a randomized phase II trial.31 Recent reviews address the topic of new immunotherapeutic strategies in AML,32, , , , –37 but thus far only HDC/IL-2 is approved for remission maintenance.